1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 

Kalorama Information's Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions.

For each company, the report provides:

Revenues
R&D Spending 2007-2013
Geographic Breakout of Revenues
Performance of Specific Products
Performance by Drug Category
Late-Stage Pipeline
Projections of Revenues to 2023

In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades.

Table Of Contents

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 
EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Future Market Opportunity
Leading Companies
INTRODUCTION
Global Pharmaceutical Market
Top 25 Pharmaceutical Companies: An Overview
Global Healthcare Spending
Aging Population and Impact on Pharmaceutical Markets
TRENDS IN PHARMACEUTICAL RESEARCH AND DEVELOPMENT
Pharmaceutical Research and Development Overview
Percent of Approvals
Selecting Better Targets
Top RandD Spenders
The Pipeline Snapshot
Expanded Options in Treating Diseases
Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Breakthrough Therapy
Pharmaceutical Regulatory Exclusivity
Pediatric Extensions
Pharmaceutical Industry—Biosimilar (Biogeneric) Development and Exclusivity
Legislation
Complications with Biosimilar Development
U.S. Exclusivity for Biosimilars
Biosimilars in Japan and China
Biosimilars in Europe
Corporate Strategy: Mergers, Acquisitions, and Collaborations
The Role of Contract Research Organizations
SANOFI
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
GLAXOSMITHKLINE PLC
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
JOHNSON and JOHNSON
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
ASTRAZENECA PLC
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
PFIZER, INC
Company Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
NOVARTIS AG
Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
ROCHE LTD.
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
MERCK and CO., INC
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
ELI LILLY AND COMPANY
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
ABBVIE, INC.
Overview
Financial Performance and Investments
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
AMGEN, INC.
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
BRISTOL-MYERS SQUIBB COMPANY
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
TAKEDA PHARMACEUTICAL CO., LTD.
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
BAYER AG
Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
NOVO NORDISK
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
OTSUKA PHARMACEUTICAL
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
MERCK KGAA
Company Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
ACTAVIS
Company Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Late Stage Pipeline
Growth Strategy
MYLAN
Company Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Pipeline
Growth Strategy
BOEHRINGER INGELHEIM GMBH
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
DAIICHI SANKYO
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
ASTELLAS
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
GILEAD SCIENCES
Company Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
BAXTER INTERNATIONAL
Company Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Pipeline
Growth Strategy
MARKET SUMMARY AND FORECAST ANALYSIS
Overview
Market Trends and Values by Therapeutic Area
Cardiovascular/Blood Market Analysis
Neurotherapeutics Market Analysis
Infection Treatments Market Analysis
Oncology Market Analysis
Respiratory and Inflammation Market Analysis
Other Drug Market Analysis
Evaluating Changes in 2013 Market Value
Year-over-Year Growth Analysis
Company Analysis
Market Forecast
Future Company Outlook
Sustainability in a Changing Pharmaceutical Industry
Conclusions

TABLE OF EXHIBITS

EXECUTIVE SUMMARY
Figure 1-1
Global Pharmaceutical Market, 2011-2013 and Forecasted 2023
Table 1-2
Global Pharmaceutical Market Forecast by Therapeutic Segment, 2023—based on late stage development projects evaluated
INTRODUCTION
Figure 2-1
Global Pharmaceutical Market by Therapeutic Area, 2011-2013 and Forecasted 2023
Table 2- 1
Top Pharmaceutical Companies, 1-25 by 2013 Pharmaceutical Sales
Figure 2-2
Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales 2013
Table 2-2
Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2012
Figure 2-3
Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2012
Table 2-3
International Population Trend Age 65+
International Population Trend Age 65+
Table 2-4
United States Population Trend Age 65+
United States Population Trend Age 65+
TRENDS IN PHARMACEUTICAL RESEARCH AND DEVELOPMENT
Table 3-1
Phases of Clinical Drug Development
Table3-2
Top RandD Spenders in the Pharmaceutical Industry2011, 2012 and 2013
Figure 3-1
Top 10 RandD Spenders in the Pharmaceutical Industry, 2013 Comparison by Company24
Table 3-3
Company Pipelines by Total Late Stage Development Projects by General Therapeutic
Segment (Top 25 Companies by Revenues)
Figure 3-2
Company Pipelines by Total Late Stage Development Projects
Figure 3-3
Company Pipelines, Leaders by Therapeutic Area
Table 3-4
Orphan Drug Designations Granted and Approved by the FDA 1983-2013
PFIZER, INC
Table 4-1
Pfizer Corporate Summary
Table 4-2
Pfizer: Total Company Revenue and Total RandD Spending 2007-2013
Figure 4-1
Pfizer: Total Company Revenue and Total RandD Spending 2007-2013
Figure 4-2
Pfizer: Break-up of Total Revenues by Region, 2013
Figure 4-3
Pfizer: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 4-4
Pfizer: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 4-3
Pfizer: Leading Pharmaceutical Products, 2013 Sales
Table 4-4
Pfizer: Late Stage Product Pipeline
Table 4-4 (continued)
Pfizer: Late Stage Product Pipeline
Figure 4-5
Pfizer: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
Table 4-5
Highlighted Corporate Developments
NOVARTIS AG
Table 5-1
Novartis Corporate Summary
Table 5-2
Novartis: Total Company Revenue and Total RandD Spending 2007-2013
Figure 5-2
Novartis: Break-up of Sales by Region, 2013
Figure 5-3
Novartis: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 5-4
Novartis: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023 .. 83
Table 5-3
Novartis: Leading Pharmaceutical Products, 2013 Sales
Table 5-4
Novartis: Late Stage Product Pipeline
Table 5-4 (continued)
Novartis: Late Stage Product Pipeline
Table 5-4 (continued)
Novartis: Late Stage Product Pipeline
Table 5-4 (continued)
Novartis: Late Stage Product Pipeline
Figure 5-5
Novartis: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011
and 2013
Table 5-5
Highlighted Corporate Developments
ROCHE LTD.
Table 6-1
Roche Corporate Summary
Table 6-2
Roche: Total Company Revenue and Total RandD Spending 2007-2013
Figure 6-2
Roche: Break-up of Sales by Region, 2013
Figure 6-3
Roche: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 6-4
Roche: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 6-3
Roche: Leading Pharmaceutical Products, 2013 Sales
Table 6-4
Roche: Late Stage Product Pipeline
Table 6-4 (continued)
Roche: Late Stage Product Pipeline
Table 6-4 (continued)
Roche: Late Stage Product Pipeline
Figure 6-5
Roche: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and
2013
Table 6-5
Highlighted Corporate Developments
MERCK and CO., INC
Table 7-1
Merck Corporate Summary
Table 7-2
Merck: Total Company Revenue and Total RandD Spending 2007-2013
Figure 7-2
Merck: Break-up of Sales by Region, 2013
Figure 7-3
Merck: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 7-4
Merck: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 7-3
Merck: Leading Pharmaceutical Products, 2013 Sales
Table 7-4
Merck: Late Stage Product Pipeline
Table 7-4 (continued)
Merck: Late Stage Product Pipeline
Figure 7-5
Merck: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
Table 7-5
Highlighted Corporate Developments
SANOFI
Table 8-1
Sanofi Corporate Summary
Table 8-2
Sanofi: Total Company Revenue and Total RandD Spending 2007-2013
Figure 8-2
Sanofi: Break-up of Sales by Region, 2013
Figure 8-3
Sanofi: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 8-4
Sanofi: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 8-3
Sanofi: Leading Pharmaceutical Products, 2013 Sales
Table 8-4
Sanofi Late Stage Product Pipeline
Table 8-4 (continued)
Sanofi Late Stage Product Pipeline
Figure 8-5
Sanofi: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and
2013
Table 8-5
Highlighted Corporate Developments
GLAXOSMITHKLINE PLC
Table 9-1
GlaxoSmithKline Corporate Summary
Table 9-2
GlaxoSmithKline: Total Company Revenue and Total RandD Spending 2007-2013
Figure 9-2
GlaxoSmithKline: Break-up of Sales by Region, 2013
Figure 9-3
GlaxoSmithKline: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 9-4
GlaxoSmithKline: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 9-3
GlaxoSmithKline: Leading Pharmaceutical Products, 2013 Sales
Table 9-4
GlaxoSmithKline: Late Stage Product Pipeline
Table 9-4 (continued)
GlaxoSmithKline: Late Stage Product Pipeline
Table 9-4 (continued)
GlaxoSmithKline: Late Stage Product Pipeline
Figure 9-5
GlaxoSmithKline: Late Stage Product Pipeline by Therapeutic AreaComparing 2009,
2011 and 2013
Table 9-5
Highlighted Corporate Developments
JOHNSON and JOHNSON
Table 10-1
Johnson and Johnson Corporate Summary
Table 10-2
Johnson and Johnson: Total Company Revenue and Total RandD Spending 2007-2013 . 149
Figure 10-2
Johnson and Johnson: Break-up of Sales by Region, 2013
Figure 10-3
Johnson and Johnson: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 10-4
Johnson and Johnson: Pharmaceutical Segment Sales 2011 through 2013 and
Forecasted 2023
Table 10-3
Johnson and Johnson: Leading Pharmaceutical Products, 2013 Sales
Table 10-4
Johnson and Johnson: Late Stage Product Pipeline
Table 10-4 (continued)
Johnson and Johnson: Late Stage Product Pipeline
Figure 10-5
Johnson and Johnson: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
Table 10-5
Highlighted Corporate Developments
ASTRAZENECA PLC
Table 11-1
AstraZeneca Corporate Summary
Table 11-2
AstraZeneca: Total Company Revenue and Total RandD Spending 2007-2013
Figure 11-2
AstraZeneca: Break-up of Sales by Region, 2013
Figure 11-3
AstraZeneca: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023164
Figure 11-4
AstraZeneca: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 11-3
AstraZeneca: Leading Pharmaceutical Products, 2013 Sales
Table 10-4
AstraZeneca: Late Stage Product Pipeline
Table 10-4 (continued)
AstraZeneca: Late Stage Product Pipeline
Table 10-4 (continued)
AstraZeneca: Late Stage Product Pipeline
Figure 11-5
AstraZeneca: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011
and 2013
Table 10-5
Highlighted Corporate Developments
ELI LILLY AND COMPANY
Table 12-1
Eli Lilly Corporate Summary
Table 12-2
Eli Lilly's Total Company Revenue and Total RandD Spending 2007-2013
Figure 12-2
Eli Lilly and Co.: Break-up of Sales by Region, 2013
Figure 12-3
Eli Lilly and Co.: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023180
Figure 12-4
Eli Lilly and Co.: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 12-3
Eli Lilly and Co.: Leading Pharmaceutical Products, 2013 Sales
Table 12-4
Eli Lilly: Late Stage Product Pipeline
Figure 12-5
Eli Lilly and Co.: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
Table 12-5
Highlighted Corporate Developments
ABBVIE, INC.
Table 13-1
AbbVie Corporate Summary
Table 13-2
AbbVie: Total Company Revenue and Total RandD Spending 2007-2013
Figure 13-2
AbbVie: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 13-3
AbbVie: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023 . 191
Table 13-3
AbbVie: Leading Pharmaceutical Products, 2013 Sales
Table 13-4
AbbVie: Late Stage Product Pipeline
Figure 13-5
AbbVie: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
Table 13-5
Highlighted Corporate Developments
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Table 14-1
Teva Pharmaceutical Corporate Summary
Table 14-2
Teva Pharmaceutical: Total Company Revenue and Total RandD Spending 2007-2013198
Figure 14-2
Teva Pharmaceutical: Break-up of Sales by Region, 2013
Figure 14-3
Teva Pharmaceutical: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 14-4
Teva Pharmaceutical: Pharmaceutical Segment Sales 2011 through 2013 and
Forecasted 2023
Table 14-3
Teva Pharmaceutical: Leading Pharmaceutical Products, 2013 Sales
Table 14-4
Teva Pharmaceutical: Late Stage Product PipelineBrand Development
Table 14-4 (continued)
Teva Pharmaceutical: Late Stage Product PipelineBrand Development
Figure 14-5
Teva Pharmaceutical: Late Stage Product Pipeline by Therapeutic Area (Brand
Therapeutics)Comparing 2009, 2011 and 2013
Table 14-5
Highlighted Corporate Developments
AMGEN, INC.
Table 15-1
Amgen Corporate Summary
Table 15-2
Amgen: Total Company Revenue and Total RandD Spending 2007-2013
Figure 15-2
Amgen: Break-up of Sales by Region, 2013
Figure 15-3
Amgen: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 15-4
Amgen: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 15-3
Amgen: Leading Pharmaceutical Products, 2013 Sales
Table 15-4
Amgen: Late Stage Product Pipeline
Table 15-4 (continued)
Amgen: Late Stage Product Pipeline
Figure 15-5
Amgen: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
Table 15-5
Highlighted Corporate Developments
BRISTOL-MYERS SQUIBB COMPANY
Table 16-1
Bristol-Myers Squibb Corporate Summary
Table 16-2
Bristol-Myers Squibb's Total Company Revenue and Total RandD Spending 2007-2013223
Figure 16-2
Bristol-Myers Squibb: Break-up of Sales by Region, 2013
Figure 16-3
Bristol-Myers Squibb: Pharmaceutical Business Performance, 2011-2013 and
Forecasted 2023
Figure 16-4
Bristol-Myers Squibb: Pharmaceutical Segment Sales 2011 through 2013 and
Forecasted 2023
Table 16-3
Bristol-Myers Squibb: Leading Pharmaceutical Products, 2013 Sales
Table 16-4
Bristol-Myers Squibb: Late Stage Product Pipeline
Table 16-4 (continued)
Bristol-Myers Squibb: Late Stage Product Pipeline
Figure 16-5
Bristol-Myers Squibb: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
Table 16-5
Highlighted Corporate Developments
TAKEDA PHARMACEUTICAL CO., LTD.
Table 17-1
Takeda Corporate Summary
Table 17-2
Takeda's Total Company Revenue* and Total RandD Spending 2007-2013
Figure 17-2
Takeda: Break-up of Sales by Region, 2013
Figure 17-3
Takeda: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 17-4
Takeda: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023 .. 241
Table 17-3
Takeda: Leading Pharmaceutical Products, 2013 Sales
Table 17-4
Takeda Pharmaceutical: Late Stage Product Pipeline
Table 17-4 (continued)
Takeda Pharmaceutical: Late Stage Product Pipeline
Figure 17-5
Takeda: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
Table 17-5
Highlighted Corporate Developments
BAYER AG
Table 18-1
Bayer Corporate Summary
Table 18-2
Bayer's Total Company Revenue and Total RandD Spending 2007-2013
Figure 18-2
Bayer: Break-up of Sales by Region, 2013
Figure 18-3
Bayer: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 18-4
Bayer: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 18-3
Bayer: Leading Pharmaceutical Products, 2013 Sales
Table 18-4
Bayer: Late Stage Product Pipeline
Table 18-4 (continued)
Bayer: Late Stage Product Pipeline
Figure 18-5
Bayer: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
Table 18-5
Highlighted Corporate Developments
NOVO NORDISK
Table 19-1
Novo Nordisk Corporate Summary
Table 19-2
Novo Nordisk: Total Company Revenue and Total RandD Spending 2007-2013
Figure 19-2
Novo Nordisk: Break-up of Sales by Region, 2013
Figure 19-3
Novo Nordisk: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023267
Figure 19-4
Novo Nordisk: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 19-3
Novo Nordisk: Leading Pharmaceutical Products, 2013 Sales
Table 19-4
Novo Nordisk: Late Stage Product Pipeline
Figure 19-5
Novo Nordisk: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
Table 19-5
Highlighted Corporate Developments
BOEHRINGER INGELHEIM GMBH
Table 20-1
Boehringer Ingelheim Corporate Summary
Table 20-2
Boehringer Ingelheim: Total Company Revenue and Total RandD Spending 2007-2013275
Figure 20-2
Boehringer Ingelheim: Break-up of Sales by Region, 2013
Figure 20-3
Boehringer Ingelheim: Pharmaceutical Business Performance, 2011-2013 and
Forecasted 2023
Figure 20-4
Boehringer Ingelheim: Pharmaceutical Segment Sales 2011 through 2013 and
Forecasted 2023
Table 20-3
Boehringer Ingelheim: Leading Pharmaceutical Products, 2013 Sales
Table 20-4
Boehringer Ingelheim: Late Stage Product Pipeline
Table 20-4 (continued)
Boehringer Ingelheim: Late Stage Product Pipeline
Figure 20-5
Boehringer Ingelheim: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
Table 20-5
Highlighted Corporate Developments
DAIICHI SANKYO
Table 21-1
Daiichi Sankyo Corporate Summary
Table 21-2
Daiichi Sankyo: Total Company Revenue and Total RandD Spending 2007-2013
Figure 21-2
Daiichi Sankyo: Break-up of Sales by Region, 2013
Figure 21-3
Daiichi Sankyo: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023291
Figure 21-4
Daiichi Sankyo: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 21-3
Daiichi Sankyo: Leading Pharmaceutical Products, 2013 Sales
Table 21-4
Daiichi Sankyo: Late Stage Product Pipeline
Figure 21-5
Daiichi Sankyo: Late Stage Product Pipeline by Therapeutic AreaComparing 2009,
2011 and 2013
Table 21-5
Highlighted Corporate Developments
ASTELLAS
Table 22-1
Astellas Corporate Summary
Table 22-2
Astellas: Total Company Revenue and Total RandD Spending 2007-2013
Figure 22-2
Astellas: Break-up of Sales by Region, 2013
Figure 22-3
Astellas: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 22-4
Astellas: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023 . 305
Table 22-3
Astellas: Leading Pharmaceutical Products, 2013 Sales
Table 22-4
Astellas: Late Stage Product Pipeline
Table 22-4 (continued)
Astellas: Late Stage Product Pipeline
Figure 22-5
Astellas: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and
2013
Table 22-5
Highlighted Corporate Developments
GILEAD SCIENCES
Table 23-1
Gilead Corporate Summary
Table 23-2
Gilead Sciences: Total Company Revenue and Total RandD Spending 2007-2013
Figure 23-1
Gilead Sciences: Total Company Revenue and Total RandD Spending 2007-2013
Figure 23-2
Gilead Sciences: Break-up of Sales by Region, 2013
Figure 23-3
Gilead Sciences: Pharmaceutical Business Performance, 2011-2013 and Forecasted
2023
Figure 23-4
Gilead Sciences: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 23-3
Gilead Sciences: Leading Pharmaceutical Products, 2013 Sales
Table 23-4
Gilead Sciences: Late Stage Product Pipeline
Figure 23-5
Gilead Sciences: Late Stage Product Pipeline by Therapeutic AreaComparing 2009, 2011 and 2013
Table 23-5
Highlighted Corporate Developments
OTSUKA PHARMACEUTICAL
Table 24-1
Otsuka Corporate Summary
Table 24-2
Otsuka Holdings: Total Company Revenue and Total RandD Spending 2007-2013
Figure 24-2
Otsuka Holdings: Break-up of Sales by Region, 2013
Figure 24-3
Otsuka Holdings: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 24-4
Otsuka Holdings: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 24-3
Otsuka Holdings: Leading Pharmaceutical Products, 2013 Sales
Table 24-4
Otsuka Holdings: Late Stage Product Pipeline
Table 24-4 (continued)
Otsuka Holdings: Late Stage Product Pipeline
Figure 24-5
Otsuka Holdings: Late Stage Product Pipeline by Therapeutic AreaComparing 2009,
2011 and 2013
Table 24-5
Highlighted Corporate Developments
MERCK KGAA
Table 25-1
Merck KGaA Corporate Summary
Table 25-2
Merck KGaA: Total Company Revenue and Total RandD Spending 2007-2013
Figure 25-1
Merck KGaA: Total Company Revenue and Total RandD Spending 2007-2013
Figure 25-2
Merck KGaA: Break-up of Sales by Region, 2013
Figure 25-3
Merck KGaA: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023342
Figure 25-4
Merck KGaA: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 25-3
Merck KGaA: Leading Pharmaceutical Products, 2013 Sales
Table 25-4
Merck KGaA: Late Stage Product Pipeline
Figure 25-5
Merck KGaA: Late Stage Product Pipeline by Therapeutic AreaComparing 2009,
2011 and 2013
Table 25-5
Corporate Development Details
ACTAVIS
Table 26-1
Actavis Corporate Summary
Table 26-2
Actavis: Total Company Revenue and Total RandD Spending 2007-2013
Figure 26-1
Actavis: Total Company Revenue and Total RandD Spending 2007-2013
Figure 26-2
Actavis: Break-up of Sales by Region, 2013
Figure 26-3
Actavis: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 26-4
Actavis: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023 . 354
Table 26-3
Actavis: Late Stage Product PipelineBrand Development
Figure 26-5
Actavis: Late Stage Product Pipeline by Therapeutic Area (Brand
Therapeutics)Comparing 2009, 2011 and 2013
Table 26-4
Highlighted Corporate Developments
MYLAN
Table 27-1
Mylan Corporate Summary
Table 27-2
Mylan: Total Company Revenue and Total RandD Spending 2007-2013
Figure 27-1
Mylan: Total Company Revenue and Total RandD Spending 2007-2013
Figure 27-2
Mylan: Break-up of Sales by Region, 2013
Figure 27-3
Mylan: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 27-4
Mylan: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 27-3
Corporate Development Details
BAXTER INTERNATIONAL
Table 28-1
Baxter Corporate Summary
Table 28-2
Baxter: Total Company Revenue and Total RandD Spending 2007-2013
Figure 28-1
Baxter: Total Company Revenue and Total RandD Spending 2007-2013
Figure 28-2
Baxter: Break-up of Sales by Region, 2013
Figure 28-3
Baxter: Pharmaceutical Business Performance, 2011-2013 and Forecasted 2023
Figure 28-4
Baxter: Pharmaceutical Segment Sales 2011 through 2013 and Forecasted 2023
Table 28-3
Highlighted Corporate Developments
MARKET SUMMARY AND FORECAST ANALYSIS
Table 29-1
Global Pharmaceutical Market, 2011-2013 and Forecasted 2023
Figure 29-1
Global Pharmaceutical Market, 2011-2013 and Forecasted 2023
Figure 29-2
Global Pharmaceutical Market by Therapeutic Area, 2011-2013 and Forecasted 2023379
Figure 29-3
Top 5 Cardiovascular/Blood Therapeutic Companies, 2013 Sales
Figure 29-4
Top 5 Neurotherapeutic Companies, 2013 Sales
Figure 29-5
Top 5 Infection Treatment Companies, 2013 Sales
Figure 29-6
Top 5 Oncology Companies, 2013 Sales
Figure 29-7
Top 5 Respiratory and Inflammation Product Companies, 2013 Sales
Figure 29-8
Top 5 Other Drug Companies, 2013 Sales
Figure 29-9
Global Pharmaceutical Market % Change by Therapeutic Segment, 2012- 2013
Table 29-2
Top Companies by 2013 Pharmaceutical Sales Growth
Figure 29-10
Global Pharmaceutical Market, Sales Growth by Company, 2012- 2013
Table 29-3
Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales 2013 Compared to 2011
Figure 29-11
Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales 2013 Comparednto 2011
Table 29-4
Top 25 Pharmaceutical Products, by 2011 and 2013 Revenues
Figure 29-12
Top 25 Pharmaceutical Products, by 2011 and 2013 Revenues
Table 29-5
Global Pharmaceutical Market Forecast by Therapeutic Segment, 2023—based on late stage development projects evaluated
Figure 29-13
Global Pharmaceutical Market Forecast by Therapeutic Segment, 2023—based on late stage development projects evaluated
Table 29-6
Evaluating Pharmaceutical Company Growth, 2013-2023
Figure 29-14
Evaluating Pharmaceutical Company Growth, 2013-2023

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.